Demonstrates MilliporeSigma’s commitment to the UK Only MilliporeSigma facility to produce both liquid and powder cell culture media Irvine, Scotland, May 27, 2019 — MilliporeSigma, a leading science and technology company, today announced the completion of a £2.7 million expansion to its Irvine biopharmaceutical production facility. The site is MilliporeSigma’s only location where both liquid and... Read more
April 30, 2019 MilliporeSigma develops fully equipped Center for Microbiological Analysis Training lab Food safety scientists to be trained in microbiological testing Ghaziabad, India, April 30, 2019 — MilliporeSigma, a leading science and technology company, today announced the handover of a fully equipped microbiological testing laboratory to the Food Safety and Standards Authority of India (FSSAI).... Read more
24 APR 2019 | BURLINGTON, MASSACHUSETTS, UNITED STATES OF AMERICA New bio-derived product is a safer, more sustainable alternative for Dimethylformamide and N-Methyl-2-pyrrolidone solvents Burlington, Massachusetts, April 24, 2019 — MilliporeSigmatoday launched Cyrene™ — a sustainable dipolar aprotic solvent, produced in two steps from a renewable cellulose source. The bio-derived alternative was created in response to the need... Read more
Your Contact:karen.tiano@emdmillipore.comPhone: +1 978 495 0093 April 4, 2019 Company wins for first-of-its-kind, single-use tangential flow filtration capsule used in ADC and monoclonal antibody bioprocessing Burlington, Massachusetts, April 4, 2019 — MilliporeSigma today announced that it has won an INTERPHEX Exhibitor Award for a new innovation in advancing next- generation bioprocessing. MilliporeSigma’s Pellicon® Capsule with Ultracel® Membrane has... Read more
02 APR 2019 | BURLINGTON, MASSACHUSETTS, UNITED STATES OF AMERICA Launch taking place at the International Pharmaceutical Expo (INTERPHEX) in New York “ContiGuous” processing will deliver seamless physical and digital integration of BioContinuum™ Platform building blocks BioContinuum™ Buffer Delivery Platform is first-of-its-kind integrated solution for streamlined buffer management Burlington, Massachusetts, April 2, 2019 – MilliporeSigmatoday unveiled its BioContinuum™ Buffer... Read more
March 14, 2019 MilliporeSigma’s global network of more than 80 CRISPR core partners promote ethical scientific exploration with genome editing via access to company’s network of experts Zhejiang University is first in China to use MilliporeSigma’s Arrayed CRISPR Library MilliporeSigma, a leading science and technology company, today announced a CRISPR core partnership with Zhejiang University... Read more
Burlington, Massachusetts, March 7, 2019 — MilliporeSigma is igniting student interest in science with its third annual Curiosity Cube® mobile science lab tour. “We’ve seen firsthand how the interactive learning that takes place inside the Curiosity Cube® can spark curiosity crucial for developing a passion for science,” said Udit Batra, CEO, MilliporeSigma. “We will continue to... Read more
04 MAR 2019 | BURLINGTON, MASSACHUSETTS, UNITED STATES OF AMERICA Patent covers paired Cas9 nickase technology to advance gene therapy and research, reduce off-target effects Marks MilliporeSigma’s 13th CRISPR patent overall Actively licensing CRISPR-related patents to interested parties Burlington, Massachusetts, March 4, 2019 – MilliporeSigma, a leader in genome editing, today announced that the Canadian Patent Office has allowed... Read more
HILTON HEAD ISLAND, South Carolina, March 4, 2019: Bruker is expanding its pharma and industrial NMR, EPR and related software solutions at PANIC 2019, the ‘Practical Applications of NMR in Industry Conference’ (www.panicnmr.com). The new productivity and compliance tools include: New Compliance Tools for Regulated Markets: Adherence to compliance with GxP is mandatory in regulated environments of... Read more
Burlington, Massachusetts, February 4, 2019 — MilliporeSigma today announced the winners of its Advance Biotech Grantprogram in Europe. The grant is given to small- and mid-size biotechnology companies that need funding and expertise to get their therapies to market. Applicants from emerging biotech companies across Europe were asked to describe their projects, the medical needs they solve,... Read more